Compare ADAM & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADAM | AURA |
|---|---|---|
| Founded | 2003 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 826.7M | 797.5M |
| IPO Year | 2003 | 2021 |
| Metric | ADAM | AURA |
|---|---|---|
| Price | $8.43 | $6.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $9.17 | ★ $20.00 |
| AVG Volume (30 Days) | ★ 921.1K | 616.2K |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | ★ 11.87% | N/A |
| EPS Growth | ★ 196.49 | N/A |
| EPS | ★ 0.87 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.08 | N/A |
| P/E Ratio | $10.11 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.45 | $4.73 |
| 52 Week High | $10.36 | $9.54 |
| Indicator | ADAM | AURA |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Adamas Trust Inc is an internally-managed REIT for U.S. federal income tax purposes, in the business of acquiring, investing in, financing, and managing mainly mortgage-related single-family and multi-family residential assets. Its objective is to deliver long-term stable distributions to its stockholders over changing economic conditions through a combination of net interest spread and capital gains from a diversified investment portfolio. The company's investment portfolio includes credit-sensitive single-family and multi-family assets.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.